Senti Biosciences, Inc. (SNTI)
Automate Your Wheel Strategy on SNTI
With Tiblio's Option Bot, you can configure your own wheel strategy including SNTI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SNTI
- Rev/Share 0.5848
- Book/Share 3.781
- PB 0.447
- Debt/Equity 0.857
- CurrentRatio 4.2153
- ROIC -0.7954
- MktCap 44077059.0
- FreeCF/Share -4.372
- PFCF -1.0069
- PE -0.3088
- Debt/Assets 0.392
- DivYield 0
- ROE -1.7725
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | SNTI | Laidlaw | -- | Buy | -- | $5 | June 6, 2025 |
News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI
Published: May 06, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc. ("Senti" or the "Company") (NASDAQ: SNTI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Senti Biosciences, Inc. – SNTI
Published: May 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Senti Biosciences, Inc. (“Senti” or the “Company”) (NASDAQ: SNTI). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Read More
Shareholder Rights Advocates at Levi & Korsinsky Investigate Senti Biosciences, Inc. (SNTI) Regarding Possible Securities Fraud Violations
Published: May 02, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Senti Biosciences, Inc. ("Senti Biosciences, Inc.") (NASDAQ:SNTI) concerning possible violations of federal securities laws. Senti issued a press release on April 28, 2025, reporting that "enrollment has been stopped" in the Investigator Sponsored Trial for its solid tumor pipeline product SN301A, conducted in collaboration with Celes Therapeutics (Shanghai) Co. Ltd.
Read More
Senti Bio Releases Virtual Investor “What This Means” Segment
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio discusses the positive data from lead program, SENTI-202, recently presented at the American Association for Cancer Research (AACR) Annual Meeting 2025
Read More
Senti Biosciences, Inc. Being Investigated on Behalf of Senti Biosciences, Inc. Investors. Contact Levi & Korsinsky For Details.
Published: May 01, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Senti Biosciences, Inc. ("Senti Biosciences, Inc.") (NASDAQ:SNTI) concerning possible violations of federal securities laws. Senti issued a press release on April 28, 2025, reporting that "enrollment has been stopped" in the Investigator Sponsored Trial for its solid tumor pipeline product SN301A, conducted in collaboration with Celes Therapeutics (Shanghai) Co. Ltd.
Read More
Shareholders That Lost Money on Senti Biosciences, Inc. (SNTI) Should Contact Levi & Korsinsky About Securities Fraud Investigation - SNTI
Published: April 30, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Senti Biosciences, Inc. ("Senti Biosciences, Inc.") (NASDAQ:SNTI) concerning possible violations of federal securities laws. Senti issued a press release on April 28, 2025, reporting that "enrollment has been stopped" in the Investigator Sponsored Trial for its solid tumor pipeline product SN301A, conducted in collaboration with Celes Therapeutics (Shanghai) Co. Ltd.
Read More
Senti Bio to Present at the Citizens JMP Life Sciences Conference
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Live video webcast presentation on Thursday, May 8 th at 1:00 PM ET Presentation will highlight the recently announced positive preliminary clinical results of lead program, SENTI-202, in the treatment of patients with Relapsed/Refractory AML SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced Timothy Lu, MD, PhD, Co-Founder and CEO of Senti Biosciences will present on Thursday, May 8, 2025 at 1:00 PM ET at the Citizens JMP Life Sciences …
Read More
Senti Bio's SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Dose Finding completed with no dose limiting toxicities and preliminary recommended Phase 2 dose (RP2D) identified 5 of 7 best overall response evaluable patients achieved ORR (3 CR, 1 CRh and 1 morphologic leukemia-free state) across all dose cohorts, including 1 CR and 1 CRh in 3 patients in preliminary RP2D cohort 4 of 4 cCR patients were measurable residual disease (MRD) negative as assessed by local standard of care Early deep responses with SENTI-202 noted across dose levels with all cCRs ongoing as of the data …
Read More
Senti Bio (NASDAQ: SNTI) to Participate in a Live Virtual Investor Closing Bell Segment
Published: April 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
Live moderated webcast with members of the Senti Bio management team on Wednesday, April 23rd at 4:00 PM ET Live moderated webcast with members of the Senti Bio management team on Wednesday, April 23rd at 4:00 PM ET
Read More
Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025
Published: April 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that three abstracts have been selected for an oral minisymposium and poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, at the McCormick Place Convention Center in Chicago, IL.
Read More
Senti Bio Strengthens Leadership Team with Strategic Hires
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
– Jay Cross, proven financial leader, appointed as CFO to drive strategic growth – – Faraz Siddiqui, expert in manufacturing operations, joins as SVP Technical Operations – SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced an expansion of its senior leadership team with the addition of Jay Cross as Chief Financial Officer and Faraz Siddiqui as Senior Vice President of Technical Operations.
Read More
About Senti Biosciences, Inc. (SNTI)
- IPO Date 2021-05-26
- Website https://www.sentibio.com
- Industry Biotechnology
- CEO Timothy K. Lu
- Employees 34